-
Development Pipeline
Development-stage programs in gout, cancer and HIV -
Gout
First and next-generation URAT1 transporter inhibitors for the treatment of hyperuricemia and gout -
Cancer
BAY 86-9766 (formerly known as RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer, is being developed under a global license agreement with Bayer Healthcare AG -
HIV
First and next-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of HIV
Scientific Publications
Scientific publications, posters and presentations relating to Ardea Biosciences’ proprietary research programs or research collaborations with other biotechnology or pharmaceutical companies will be posted once they are available.
Company Presentations |
|
 |
Ardea Company Update, January 9, 2012 |
Latest News
- 19 Dec 2011 Ardea Biosciences Initiates Phase 3 Clinical Development Program for Lesinurad
- 15 Nov 2011 Ardea Biosciences to Present at Upcoming Investor Conferences
- 07 Nov 2011 Ardea Biosciences Provides Additional Positive Clinical Results for Lesinurad and Initial Clinical Results for RDEA3170 at the 2011 ACR/ARHP Annual Scientific Meeting
Upcoming Events
There are currently no upcoming events scheduled.